Monoclonal antibody therapies targeting CD20 (rituximab, ofatumumab, and obinutuzumab) and CD52 (alemtuzumab) have a proven track record of efficacy for CLL treatment. The gene discussed is CD52; the disease is B-cell chronic lymphocytic leukemia.